OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk
Dan Cheng, Zhuogui Lei, Kin Chu, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 12
Dan Cheng, Zhuogui Lei, Kin Chu, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 12
Showing 12 citing articles:
Mitochondrial fission and fusion in neurodegenerative diseases:Ca2+ signalling
Xuan Liu, Tianjiao Li, Xiaoming Tu, et al.
Molecular and Cellular Neuroscience (2025), pp. 103992-103992
Closed Access | Times Cited: 1
Xuan Liu, Tianjiao Li, Xiaoming Tu, et al.
Molecular and Cellular Neuroscience (2025), pp. 103992-103992
Closed Access | Times Cited: 1
Exploring DMT: Endogenous Role and Therapeutic Potential
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access
J. Schimmelpfennig, Kamila Jankowiak-Siuda
Neuropharmacology (2025), pp. 110314-110314
Open Access
N, N-dimethyltryptamine (DMT) in rodent brain: Concentrations, distribution, and recent pharmacological data
Steven A. Barker
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111259-111259
Closed Access
Steven A. Barker
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025), pp. 111259-111259
Closed Access
Mitochondrial Dysfunction in Neurodegenerative Diseases: Mechanisms and Corresponding Therapeutic Strategies
Kai Meng, Hongyun Jia, Xiaoqing Hou, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 327-327
Open Access
Kai Meng, Hongyun Jia, Xiaoqing Hou, et al.
Biomedicines (2025) Vol. 13, Iss. 2, pp. 327-327
Open Access
Sigma-1 receptor agonist PRE-084 increases BDNF by activating the ERK/CREB pathway to rescue learning and memory impairment caused by type II diabetes
Leilei Shi, Mingmei Wang, Ruixuan Yu, et al.
Behavioural Brain Research (2025), pp. 115493-115493
Closed Access
Leilei Shi, Mingmei Wang, Ruixuan Yu, et al.
Behavioural Brain Research (2025), pp. 115493-115493
Closed Access
P-hydroxybenzaldehyde protects Caenorhabditis elegans from oxidative stress and β-amyloid toxicity
Xingzhi Yu, Jie Tao, Tian Xiao, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 3
Xingzhi Yu, Jie Tao, Tian Xiao, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 3
Novel extended-release transdermal formulations of the psychedelic N,N-dimethyltryptamine (DMT)
Christopher G. Witowski, M. Hess, N. Jones, et al.
European Journal of Pharmaceutical Sciences (2024) Vol. 199, pp. 106803-106803
Open Access | Times Cited: 3
Christopher G. Witowski, M. Hess, N. Jones, et al.
European Journal of Pharmaceutical Sciences (2024) Vol. 199, pp. 106803-106803
Open Access | Times Cited: 3
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics
Cong Lin, Xiubo Du, Xiaohui Wang
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access
Cong Lin, Xiubo Du, Xiaohui Wang
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access
Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics
Cristiano Chaves, Rafael G. dos Santos, Serdar Dursun, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access
Cristiano Chaves, Rafael G. dos Santos, Serdar Dursun, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access
Ayahuasca: pharmacology, safety, and therapeutic effects
Rafael G. dos Santos, Jaime E. C. Hallak
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access
Rafael G. dos Santos, Jaime E. C. Hallak
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access
Exploring Endogenous Tryptamines: Overlooked Agents Against Fibrosis in Chronic Disease? A Narrative Review
Hunter Korsmo
Livers (2024) Vol. 4, Iss. 4, pp. 615-637
Open Access
Hunter Korsmo
Livers (2024) Vol. 4, Iss. 4, pp. 615-637
Open Access
Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential
Carolina Echeverry, Mariana Pazos, Maximiliano Torres-Pérez, et al.
Neuroscience (2024)
Closed Access
Carolina Echeverry, Mariana Pazos, Maximiliano Torres-Pérez, et al.
Neuroscience (2024)
Closed Access
